The TissueCypher® Barrett’s Esophagus Assay identifies patients with Barrett’s esophagus that progress to esophageal cancer at a rate 5 to 10 times higher than the current standard of care. TissueCypher® delivers the holy grail of Barrett’s esophagus: predicting progression and non-progression.

Have questions about integrating
TissueCypher® into your practice?

Contact us to discuss the science behind our technology
and how TissueCypher® can be integrated into your practice.